Insulin Detemir (d-INS) (5 IU/kg; i.p.; once daily; 2 weeks) demonstrates weight-sparing effects compared with other insulin formulations, and shows a intestinal tissues preference, potentially involving the activation of insulin/-catenin/CREB signaling pathways[1].
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment (File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)
Remove